ALDX

Aldeyra Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.63

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %6.4 / %30

Non-compliant assets / Total market cap %16.5 / %30

Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

Website

Analysis (Turkish): ALDX Hissesi Caiz mi, Helal mi? Aldeyra Therapeutics, Inc. Katılım Analizi